Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30254
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcCleary, Nadine J-
dc.contributor.authorHarmsen, William S-
dc.contributor.authorHaakenstad, Ellana-
dc.contributor.authorCleary, James M-
dc.contributor.authorMeyerhardt, Jeffrey A-
dc.contributor.authorZalcberg, John-
dc.contributor.authorAdams, Richard-
dc.contributor.authorGrothey, Axel-
dc.contributor.authorSobrero, Alberto F-
dc.contributor.authorVan Cutsem, Eric-
dc.contributor.authorGoldberg, Richard M-
dc.contributor.authorPeeters, Marc-
dc.contributor.authorTabernero, Josep-
dc.contributor.authorSeymour, Matt-
dc.contributor.authorSaltz, Leonard B-
dc.contributor.authorGiantonio, Bruce J-
dc.contributor.authorArnold, Dirk-
dc.contributor.authorRothenberg, Mace L-
dc.contributor.authorKoopman, Miriam-
dc.contributor.authorSchmoll, Hans-Joachim-
dc.contributor.authorPitot, Henry C-
dc.contributor.authorHoff, Paulo M-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorMasi, Gianluca-
dc.contributor.authorSouglakos, John-
dc.contributor.authorBokemeyer, Carsten-
dc.contributor.authorHeinemann, Volker-
dc.contributor.authorYoshino, Takayuki-
dc.contributor.authorChibaudel, Benoist-
dc.contributor.authordeGramont, Aimery-
dc.contributor.authorShi, Qian-
dc.contributor.authorLichtman, Stuart M-
dc.date.accessioned2022-06-23T00:31:34Z-
dc.date.available2022-06-23T00:31:34Z-
dc.date.issued2022-03-02-
dc.identifier.citationJNCI cancer spectrum 2022; 6(2)en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30254-
dc.description.abstractWe evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials. Associations between clinical and disease characteristics, time to initial progression, and rate of receipt of second-line therapy were evaluated. TTP and overall survival (OS) were compared between older and younger adults in first- and second-line trials by Cox regression, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites and presence of metastasis in the lung, liver, or peritoneum. All statistical tests were 2-sided. Older adults comprised 16.4% of patients on first-line trials (870 total older adults aged >70 years; 4419 total younger adults aged ≤70 years, on first-line trials). Older adults and those with Eastern Cooperative Oncology Group Performance Status >0 were less likely to receive second-line therapy than younger adults. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariable analysis (odds ratio = 1.11, 95% confidence interval = 1.02 to 1.21, P = .01). Older and younger adults enrolled in second-line trials experienced similar median TTP and median OS (median TTP = 5.1 vs 5.2 months, respectively; median OS = 11.6 vs 12.4 months, respectively). Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy.en
dc.language.isoeng
dc.titleMetastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.en
dc.typeJournal Articleen
dc.identifier.journaltitleJNCI cancer spectrumen
dc.identifier.affiliationAustin Healthen
dc.identifier.affiliationGastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA..en
dc.identifier.affiliationMonash University, Melbourne, Australia..en
dc.identifier.affiliationUniversity of Sydney Medical School, Sydney, Australia..en
dc.identifier.affiliationDepartment of Health Science Research, Mayo Clinic, Rochester, MN, USA..en
dc.identifier.affiliationCardiff University and Velindre Cancer Centre, Cardiff, UK..en
dc.identifier.affiliationWest Cancer Center and Research Institute, OneOncology, Germantown, TN, USA..en
dc.identifier.affiliationMedical Oncology Unit, Ospedale San Martino, Genova, Italy..en
dc.identifier.affiliationUniversity of Leuven, Leuven, Belgium..en
dc.identifier.affiliationWest Virginia University Cancer Institute and the Mary Babb Randolph Cancer Center, Morgantown, WV, USA..en
dc.identifier.affiliationDepartment of Oncology, Antwerp University Hospital, Antwerp, Belgium..en
dc.identifier.affiliationVall d'Hebron University Hospital and Institute of Oncology (VHIO), Institute of Oncology Barcelona-Quiron, UVic-UCC, Barcelona, Spain..en
dc.identifier.affiliationNIHR Clinical Research Network, Leeds, UK..en
dc.identifier.affiliationMemorial Sloan Kettering Cancer Center, New York, NY, USA..en
dc.identifier.affiliationPerelman School of Medicine Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA..en
dc.identifier.affiliationInstituto CUF de Oncologia, Lisbon, Portugal..en
dc.identifier.affiliationGlobal Product Development, Pfizer Inc, New York, NY, USA..en
dc.identifier.affiliationDepartment of Medical Oncology, University Medical Center Utrecht, University of Urtrecht, Utrecht, Netherlands..en
dc.identifier.affiliationKlinik fur Innere Med IV, University Clinic Halle (Saale), Halle, Germany..en
dc.identifier.affiliationDepartment of Oncology, Mayo Clinic, Rochester, MN, USA..en
dc.identifier.affiliationCentro de Oncologia de Brasilia do Sirio Libanes-Unidade Lago Sul, Siro Libanes, Brazil..en
dc.identifier.affiliationDepartment of Oncology, University of Pisa, Pisa, Italy..en
dc.identifier.affiliationDepartment of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece..en
dc.identifier.affiliationUniversitatsklinikum Hamburg-Eppendorf, Hamburg-Eppendorf, Germany..en
dc.identifier.affiliationDepartment of Hematology/Oncology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Germany..en
dc.identifier.affiliationNational Cancer Center Hospital East, Kashiwa, Japan..en
dc.identifier.affiliationDepartment of Medical Oncology, Institut Franco-Britannique, Levallois-Perret, France..en
dc.identifier.affiliationSt. James's Hospital and University of Leeds, Leeds, UK..en
dc.identifier.affiliationAsklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany..en
dc.identifier.affiliationMartin Luther University, Halle, Germany..en
dc.identifier.affiliationUniversidade de São Paulo Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35603849/en
dc.identifier.doi10.1093/jncics/pkac014en
dc.type.contentTexten
dc.identifier.orcid0000-0003-2377-8301en
dc.identifier.orcid0000-0002-6624-0782en
dc.identifier.orcid0000-0003-3915-7243en
dc.identifier.orcid0000-0002-9341-6499en
dc.identifier.orcid0000-0001-7764-673Xen
dc.identifier.orcid0000-0002-6372-1230en
dc.identifier.orcid0000-0003-0308-8223en
dc.identifier.orcid0000-0003-4969-2303en
dc.identifier.orcid0000-0002-2495-8139en
dc.identifier.orcid0000-0002-2441-9629en
dc.identifier.orcid0000-0001-8353-4670en
dc.identifier.orcid0000-0003-1550-1978en
dc.identifier.orcid0000-0003-2613-5168en
dc.identifier.orcid0000-0001-6071-7810en
dc.identifier.orcid0000-0002-1349-3321en
dc.identifier.orcid0000-0002-0489-4756en
dc.identifier.orcid0000-0001-7940-9877en
dc.identifier.orcid0000-0002-4640-8832en
dc.identifier.orcid0000-0003-4146-6192en
dc.identifier.pubmedid35603849
local.name.researcherTebbutt, Niall C
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Nov 3, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.